It is easy to detect heart and kidney disease even through a simple blood test in diabetic patients: Study

According to a study, heart disease and kidney disease can be detected in diabetes type-2 patients through a simple blood test.

According to a study, heart disease and kidney disease can be detected in diabetes type-2 patients through a simple blood test. According to research published in 'American Heart', this test was done on more than 2,500 people with type 2 diabetes and kidney disease and found that there are four biomarkers in the blood test that can detect heart disease and kidney disease. are helpful. "High levels of certain biomarkers are indicators of heart and kidney complications and may help predict the risk of future disease progression," said lead author James Januzzi, a cardiologist at Harvard Medical School and Massachusetts General Hospital.

Those who took canagliflozin, a sodium glucose co-transporter 2 inhibitor (SGLT2 inhibitor), had lower levels of four biomarkers during the three-year study period than those who took a placebo. Canagliflozin is a third-line drug used in combination with metformin. The latter should be tried, which is the first line drug for type 2 diabetes. Treatment with canagliflozin helped to substantially reduce the risk of hospitalization in patients considered at highest risk of developing heart failure and other heart-related complications.

Kidney and heart disease risk seen

Researchers analyzed biomarker data from blood samples from 2,627 people to assess the effect of canagliflozin on the concentrations of four biomarkers. Patients were divided into low-, medium- and high-risk categories. Those at highest risk showed dramatically higher rates of progressive kidney and heart disease complications during the three-year study period.

blood test biomarkers

The analysis found that higher concentrations of each biomarker at the start of the study strongly predicted the severity of a participant's heart and kidney problems. People taking canagliflozin had lower concentrations of each of the four biomarkers after one year and three years than those taking a placebo.

After one year, levels of all biomarkers increased from 3 percent to 10 percent in participants taking canagliflozin, compared to 6 percent to 29 percent in those taking the placebo. It was reassuring to know that canagliflozin reduced the majority of complications. Helped to reduce the risk in most susceptible people. Future studies are needed to better understand how type 2 diabetes develops and progresses with kidney disease so that we can begin life-saving treatments before symptoms of heart and kidney disease appear.

Disclaimer: Before following the methods, methods and suggestions mentioned in this article, do take the advice of a doctor or a related expert.